Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Denali Therapeutics Inc.    DNLI

DENALI THERAPEUTICS INC.

(DNLI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
64.66(c) 62.92(c) 61.36(c) 58.7(c) 61.04(c) Last
1 061 462 562 114 614 029 664 229 643 029 Volume
-9.94% -2.69% -2.48% -4.34% +3.99% Change
More quotes
Financials (USD)
Sales 2021 136 M - -
Net income 2021 -204 M - -
Net cash position 2021 1 757 M - -
P/E ratio 2021 -35,9x
Yield 2021 -
Sales 2022 96,6 M - -
Net income 2022 -270 M - -
Net cash position 2022 1 300 M - -
P/E ratio 2022 -27,4x
Yield 2022 -
Capitalization 7 385 M 7 385 M -
EV / Sales 2021 41,3x
EV / Sales 2022 63,0x
Nbr of Employees 291
Free-Float 81,7%
More Financials
Company
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes... 
More about the company
Notations Surperformance© of Denali Therapeutics Inc.
Trading Rating : Investor Rating :
More Ratings
All news about DENALI THERAPEUTICS INC.
02/26DENALI THERAPEUTICS  : HC Wainwright Adjusts Denali Therapeutics' Price Target t..
MT
02/26DENALI THERAPEUTICS  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
02/25DENALI THERAPEUTICS INC.  : Results of Operations and Financial Condition (form ..
AQ
02/25DENALI THERAPEUTICS  : Earnings Flash (DNLI) DENALI THERAPEUTICS Posts Q4 Revenu..
MT
02/25Denali Therapeutics Reports Full Year 2020 Financial Results and Business Hig..
GL
02/19DENALI THERAPEUTICS  : Continued Level of Significant Insider Selling at Denali ..
MT
02/18INSIDER TRENDS : Insider Adds to Selling Trend at Denali Therapeutics
MT
02/17DENALI THERAPEUTICS  : DNLI) Insiders Make Significant Share Sales Extending the..
MT
02/17INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at Denali Therapeutics
MT
02/16INSIDER TRENDS : Insider 90-Day Selling Trend Extended at Denali Therapeutics
MT
02/16INSIDER TRENDS : Insider Adds to Selling Trend at Denali Therapeutics
MT
02/16INSIDER TRENDS : Denali Therapeutics Insider Prolongs 90-Day Selling Trend
MT
02/16INSIDER TRENDS : Selling By Insiders Lingers at Denali Therapeutics
MT
02/15DENALI THERAPEUTICS REPORTS POSITIVE : IDS in Patients with Hunter Syndrome
AQ
02/12DENALI THERAPEUTICS  : Reports Positive Interim Data From Phase 1/2 Study of DNL..
MT
More news
News in other languages on DENALI THERAPEUTICS INC.

- No features available -

More news
Analyst Recommendations on DENALI THERAPEUTICS INC.
More recommendations
Chart DENALI THERAPEUTICS INC.
Duration : Period :
Denali Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DENALI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 90,67 $
Last Close Price 61,04 $
Spread / Highest target 73,7%
Spread / Average Target 48,5%
Spread / Lowest Target -1,70%
EPS Revisions
Managers and Directors
NameTitle
Ryan J. Watts President, Chief Executive Officer & Director
Steve E. Krognes Treasurer, Chief Financial & Accounting Officer
Vicki L. Sato Non-Executive Chairman
Carole Ho Chief Medical Officer & Head-Development
Dana Andersen CTO & Chief Manufacturing Officer
Sector and Competitors
1st jan.Capitalization (M$)
DENALI THERAPEUTICS INC.-29.92%7 102
GILEAD SCIENCES, INC.7.71%79 454
VERTEX PHARMACEUTICALS-12.08%54 017
WUXI APPTEC CO., LTD.2.79%52 082
REGENERON PHARMACEUTICALS-7.53%46 800
BEIGENE, LTD.11.93%26 493